Europe Diabetic Neuropathy Treatment Market Size, Share & Trends Analysis Report By Distribution Channel, By Drug Class, By Disorder Type, By Country and Growth Forecast, 2024 - 2031

The Europe Diabetic Neuropathy Treatment Market would witness market growth of 6.9% CAGR during the forecast period (2024-2031).

The Germany market dominated the Europe Diabetic Neuropathy Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $454 million by 2031. The UK market is exhibiting a CAGR of 6% during (2024 - 2031). Additionally, The France market would experience a CAGR of 7.8% during (2024 - 2031).

As the condition's prevalence rises and the need for effective therapeutic interventions intensifies, the market for it is undergoing a rapid evolution. In recent years, there have been significant advancements in the understanding of this and the development of new treatment options.

Additionally, due to these developments, the management of this has shifted to place more importance on early detection and intervention to impede or halt the progression of nerve damage.

European research and innovation efforts contribute to developing novel and more effective treatment modalities for diabetic neuropathy. This includes discovering new pharmacological agents, biotechnological therapies, and medical devices specifically designed to target neuropathic symptoms. According to the European Commission, research and innovation on diabetes and related factors, such as obesity, has been a longstanding priority for the EU. Over EUR 1.25 billion has been devoted to support research in the last decade.

Free Valuable Insights: The Global Diabetic Neuropathy Treatment Market will Hit USD 7.4 Billion by 2031, at a CAGR of 7.3%

Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Retail Pharmacies and Others. Based on Drug Class, the market is segmented into Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Antidepressants, Opioid, Capsaicin and Others. Based on Disorder Type, the market is segmented into Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy and Focal Neuropathy. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

List of Key Companies Profiled

• Abbott Laboratories
• Eli Lilly And Company
• Pfizer, Inc.
• Lupin Limited
• Astellas Pharma, Inc.
• Glenmark Pharmaceuticals Limited
• Boehringer Ingelheim International GmbH
• Novartis AG
• McKesson Corporation
• GlaxoSmithKline PLC (GSK)

Europe Diabetic Neuropathy Treatment Market Report Segmentation

By Distribution Channel

• Hospitals Pharmacies
• Retail Pharmacies
• Others

By Drug Class

• Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
• Antidepressants
• Opioid
• Capsaicin
• Others

By Disorder Type

• Peripheral Neuropathy
• Autonomic Neuropathy
• Proximal Neuropathy
• Focal Neuropathy

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Diabetic Neuropathy Treatment Market, by Distribution Channel
1.4.2 Europe Diabetic Neuropathy Treatment Market, by Drug Class
1.4.3 Europe Diabetic Neuropathy Treatment Market, by Disorder Type
1.4.4 Europe Diabetic Neuropathy Treatment Market, by Country
1.5 Methodology for the research

Chapter 2. Market at a Glance
2.1 Key Highlights

Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
3.3 Porter Five Forces Analysis

Chapter 4. Europe Diabetic Neuropathy Treatment Market by Distribution Channel
4.1 Europe Hospitals Pharmacies Market by Country
4.2 Europe Retail Pharmacies Market by Country
4.3 Europe Others Market by Country

Chapter 5. Europe Diabetic Neuropathy Treatment Market by Drug Class
5.1 Europe Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market by Country
5.2 Europe Antidepressants Market by Country
5.3 Europe Opioid Market by Country
5.4 Europe Capsaicin Market by Country
5.5 Europe Others Market by Country

Chapter 6. Europe Diabetic Neuropathy Treatment Market by Disorder Type
6.1 Europe Peripheral Neuropathy Market by Country
6.2 Europe Autonomic Neuropathy Market by Country
6.3 Europe Proximal Neuropathy Market by Country
6.4 Europe Focal Neuropathy Market by Country

Chapter 7. Europe Diabetic Neuropathy Treatment Market by Country
7.1 Germany Diabetic Neuropathy Treatment Market
7.1.1 Germany Diabetic Neuropathy Treatment Market by Distribution Channel
7.1.2 Germany Diabetic Neuropathy Treatment Market by Drug Class
7.1.3 Germany Diabetic Neuropathy Treatment Market by Disorder Type
7.2 UK Diabetic Neuropathy Treatment Market
7.2.1 UK Diabetic Neuropathy Treatment Market by Distribution Channel
7.2.2 UK Diabetic Neuropathy Treatment Market by Drug Class
7.2.3 UK Diabetic Neuropathy Treatment Market by Disorder Type
7.3 France Diabetic Neuropathy Treatment Market
7.3.1 France Diabetic Neuropathy Treatment Market by Distribution Channel
7.3.2 France Diabetic Neuropathy Treatment Market by Drug Class
7.3.3 France Diabetic Neuropathy Treatment Market by Disorder Type
7.4 Russia Diabetic Neuropathy Treatment Market
7.4.1 Russia Diabetic Neuropathy Treatment Market by Distribution Channel
7.4.2 Russia Diabetic Neuropathy Treatment Market by Drug Class
7.4.3 Russia Diabetic Neuropathy Treatment Market by Disorder Type
7.5 Spain Diabetic Neuropathy Treatment Market
7.5.1 Spain Diabetic Neuropathy Treatment Market by Distribution Channel
7.5.2 Spain Diabetic Neuropathy Treatment Market by Drug Class
7.5.3 Spain Diabetic Neuropathy Treatment Market by Disorder Type
7.6 Italy Diabetic Neuropathy Treatment Market
7.6.1 Italy Diabetic Neuropathy Treatment Market by Distribution Channel
7.6.2 Italy Diabetic Neuropathy Treatment Market by Drug Class
7.6.3 Italy Diabetic Neuropathy Treatment Market by Disorder Type
7.7 Rest of Europe Diabetic Neuropathy Treatment Market
7.7.1 Rest of Europe Diabetic Neuropathy Treatment Market by Distribution Channel
7.7.2 Rest of Europe Diabetic Neuropathy Treatment Market by Drug Class
7.7.3 Rest of Europe Diabetic Neuropathy Treatment Market by Disorder Type

Chapter 8. Company Profiles
8.1 Abbott Laboratories
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Acquisition and Mergers:
8.1.5.2 Trial and Approval:
8.1.6 SWOT Analysis
8.2 Eli Lilly And Company
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Acquisition and Mergers:
8.2.6 SWOT Analysis
8.3 Pfizer, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional & Segmental Analysis
8.3.4 Research & Development Expense
8.3.5 SWOT Analysis
8.4 Lupin Limited
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expense
8.4.5 SWOT Analysis
8.5 Astellas Pharma, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expense
8.5.5 SWOT Analysis
8.6 Glenmark Pharmaceuticals Limited
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 SWOT Analysis
8.7 Boehringer Ingelheim International GmbH
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Regional & Segmental Analysis
8.7.4 Research & Development Expenses
8.7.5 SWOT Analysis
8.8 Novartis AG
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Acquisition and Mergers:
8.8.6 SWOT Analysis
8.9 McKesson Corporation
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental Analysis
8.9.4 Research & Development Expense
8.9.5 SWOT Analysis
8.10. GlaxoSmithKline PLC (GSK)
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expense
8.10.5 SWOT Analysis

TABLE 1 Europe Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 2 Europe Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 3 Europe Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 4 Europe Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 5 Europe Hospitals Pharmacies Market by Country, 2020 - 2023, USD Million
TABLE 6 Europe Hospitals Pharmacies Market by Country, 2024 - 2031, USD Million
TABLE 7 Europe Retail Pharmacies Market by Country, 2020 - 2023, USD Million
TABLE 8 Europe Retail Pharmacies Market by Country, 2024 - 2031, USD Million
TABLE 9 Europe Others Market by Country, 2020 - 2023, USD Million
TABLE 10 Europe Others Market by Country, 2024 - 2031, USD Million
TABLE 11 Europe Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 12 Europe Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 13 Europe Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market by Country, 2020 - 2023, USD Million
TABLE 14 Europe Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market by Country, 2024 - 2031, USD Million
TABLE 15 Europe Antidepressants Market by Country, 2020 - 2023, USD Million
TABLE 16 Europe Antidepressants Market by Country, 2024 - 2031, USD Million
TABLE 17 Europe Opioid Market by Country, 2020 - 2023, USD Million
TABLE 18 Europe Opioid Market by Country, 2024 - 2031, USD Million
TABLE 19 Europe Capsaicin Market by Country, 2020 - 2023, USD Million
TABLE 20 Europe Capsaicin Market by Country, 2024 - 2031, USD Million
TABLE 21 Europe Others Market by Country, 2020 - 2023, USD Million
TABLE 22 Europe Others Market by Country, 2024 - 2031, USD Million
TABLE 23 Europe Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 24 Europe Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 25 Europe Peripheral Neuropathy Market by Country, 2020 - 2023, USD Million
TABLE 26 Europe Peripheral Neuropathy Market by Country, 2024 - 2031, USD Million
TABLE 27 Europe Autonomic Neuropathy Market by Country, 2020 - 2023, USD Million
TABLE 28 Europe Autonomic Neuropathy Market by Country, 2024 - 2031, USD Million
TABLE 29 Europe Proximal Neuropathy Market by Country, 2020 - 2023, USD Million
TABLE 30 Europe Proximal Neuropathy Market by Country, 2024 - 2031, USD Million
TABLE 31 Europe Focal Neuropathy Market by Country, 2020 - 2023, USD Million
TABLE 32 Europe Focal Neuropathy Market by Country, 2024 - 2031, USD Million
TABLE 33 Europe Diabetic Neuropathy Treatment Market by Country, 2020 - 2023, USD Million
TABLE 34 Europe Diabetic Neuropathy Treatment Market by Country, 2024 - 2031, USD Million
TABLE 35 Germany Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 36 Germany Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 37 Germany Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 38 Germany Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 39 Germany Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 40 Germany Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 41 Germany Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 42 Germany Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 43 UK Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 44 UK Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 45 UK Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 46 UK Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 47 UK Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 48 UK Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 49 UK Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 50 UK Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 51 France Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 52 France Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 53 France Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 54 France Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 55 France Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 56 France Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 57 France Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 58 France Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 59 Russia Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 60 Russia Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 61 Russia Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 62 Russia Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 63 Russia Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 64 Russia Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 65 Russia Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 66 Russia Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 67 Spain Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 68 Spain Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 69 Spain Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 70 Spain Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 71 Spain Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 72 Spain Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 73 Spain Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 74 Spain Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 75 Italy Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 76 Italy Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 77 Italy Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 78 Italy Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 79 Italy Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 80 Italy Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 81 Italy Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 82 Italy Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 83 Rest of Europe Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 84 Rest of Europe Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 85 Rest of Europe Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 86 Rest of Europe Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 87 Rest of Europe Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 88 Rest of Europe Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 89 Rest of Europe Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 90 Rest of Europe Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 91 Key Information – Abbott Laboratories
TABLE 92 Key Information – Eli Lilly And Company
TABLE 93 Key Information – Pfizer, Inc.
TABLE 94 Key Information – Lupin Limited
TABLE 95 key information – Astellas Pharma, Inc.
TABLE 96 Key Information – Glenmark Pharmaceuticals Limited
TABLE 97 Key Information – Boehringer Ingelheim International GmbH
TABLE 98 Key Information – Novartis AG
TABLE 99 Key Information – McKesson Corporation
TABLE 100 Key Information – GlaxoSmithKline PLC

List of Figures
FIG 1 Methodology for the research
FIG 2 Europe Diabetic Neuropathy Treatment Market, 2020 - 2031, USD Million
FIG 3 Key Factors Impacting Diabetic Neuropathy Treatment Market
FIG 4 Porter’s Five Forces Analysis – Diabetic Neuropathy Treatment Market
FIG 5 Europe Diabetic Neuropathy Treatment Market share by Distribution Channel, 2023
FIG 6 Europe Diabetic Neuropathy Treatment Market share by Distribution Channel, 2031
FIG 7 Europe Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2031, USD Million
FIG 8 Europe Diabetic Neuropathy Treatment Market share by Drug Class, 2023
FIG 9 Europe Diabetic Neuropathy Treatment Market share by Drug Class, 2031
FIG 10 Europe Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2031, USD Million
FIG 11 Europe Diabetic Neuropathy Treatment Market share by Disorder Type, 2023
FIG 12 Europe Diabetic Neuropathy Treatment Market share by Disorder Type, 2031
FIG 13 Europe Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2031, USD Million
FIG 14 Europe Diabetic Neuropathy Treatment Market share by Country, 2023
FIG 15 Europe Diabetic Neuropathy Treatment Market share by Country, 2031
FIG 16 Europe Diabetic Neuropathy Treatment Market by Country, 2020 - 2031, USD Million
FIG 17 Recent strategies and developments: Abbott Laboratories
FIG 18 SWOT Analysis: Abbott Laboratories
FIG 19 Swot Analysis: Eli Lilly And Company
FIG 20 SWOT Analysis: Pfizer, Inc.
FIG 21 SWOT Analysis: Lupin Limited
FIG 22 SWOT Analysis: Astellas Pharma, Inc.
FIG 23 SWOT Analysis: Glenmark Pharmaceuticals Limited
FIG 24 SWOT Analysis: Boehringer Ingelheim International GmbH
FIG 25 SWOT Analysis: Novartis AG
FIG 26 SWOT Analysis: McKesson Corporation
FIG 27 SWOT Analysis: GlaxoSmithKline PLC